U.S. Chemicals Stock News

The simplest way to invest in stocks is to buy exchange traded funds. But in our experience, buying the right stocks...

There wouldn't be many who think ProPetro Holding Corp.'s ( NYSE:PUMP ) price-to-sales (or "P/S") ratio of 0.8x is...

While Angi Inc. ( NASDAQ:ANGI ) might not have the largest market cap around , it saw a double-digit share price rise...

Key Insights Significantly high institutional ownership implies Forum Energy Technologies' stock price is sensitive to...

Black Diamond Therapeutics (BDTX) just released topline Phase 2 data for its EGFR inhibitor silevertinib in frontline non small cell lung cancer, while also laying out plans for a randomized Phase 2 trial in newly diagnosed glioblastoma. See our latest analysis for Black Diamond Therapeutics. The latest silevertinib update landed against a choppy backdrop for Black Diamond Therapeutics, with a sharp 1 day share price return of negative 22.03 percent and a 7 day share price return of negative...

Wondering if Kellanova is still fairly priced after its long run, or if there is more upside left in the tank? This breakdown will help you decide whether the current share price actually makes sense. The stock has been mostly treading water in the short term, down 0.6% over the last week and roughly flat over the past month at 0.1%. However, that hides a steadier climb of 2.6% year to date and 6.2% over the last year, compounding into 32.5% and 69.5% gains over the past 3 and 5...

Oppenheimer recently initiated coverage on Theravance Biopharma with an Outperform rating, emphasizing the importance of the Phase 3 ampreloxetine readout expected in the first quarter of 2026 and the company’s virtual key opinion leader event on this program. The focus on ampreloxetine as a potential billion-dollar therapy in a rare neurogenic condition highlights how pivotal this single late-stage asset has become for Theravance’s future prospects and risk profile. We’ll now explore how...

Blue Hat Interactive Entertainment Technology (NasdaqCM:BHAT) has just posted its H1 2025 scorecard, with trailing twelve month revenue sitting at about $19.0 million and net income of roughly -$9.1 million, keeping EPS around $0 over that span. The company has seen revenue move from $27.4 million in H2 2023 to $18.7 million in H2 2024, while net income excluding extraordinary items shifted from -$22.3 million to -$8.2 million. The latest numbers still leave investors focused squarely on...

Marvell Technology (MRVL) has turned in a punchy Q3 2026 print, with revenue of about $2.1 billion and basic EPS of $2.22, while net income (excluding extra items) came in at $1.9 billion as the latest marker of its profitability turnaround. The company has seen revenue move from $1.52 billion in Q3 2025 to $2.07 billion in Q3 2026 alongside a swing in net income from a loss of $676.3 million to a $1.9 billion profit, setting up a quarter where margins look materially healthier and far more...

Janux Therapeutics recently reported positive updated interim Phase 1 data for its PSMA-directed TRACTr candidate JANX007 in metastatic castration-resistant prostate cancer, based on 109 treated patients as of the October 15, 2025 cutoff, and held a virtual event on December 1 to discuss the results. The update highlights not only progress for JANX007 but also reinforces Janux’s broader TRACTr and ARM platforms, which span multiple solid tumors and an emerging CD19 program in autoimmune...

The board of NetApp, Inc. ( NASDAQ:NTAP ) has announced that it will pay a dividend of $0.52 per share on the 21st of...

Recent data showing a sharp drop in trading volume but steady growth in verified accounts at Coincheck Group (CNCK) has investors rethinking how this crypto exchange makes money and where future growth might come from. See our latest analysis for Coincheck Group. Despite the weak year to date share price return and a 1 year total shareholder return of around minus 49 percent, the recent 7 day share price return of roughly 103 percent and 30 day gain near 78 percent suggest momentum is...

Investors were underwhelmed by the solid earnings posted by Veeva Systems Inc. ( NYSE:VEEV ) recently. We have done...

In recent sessions, major U.S. stock indexes have shown resilience, rising despite initial declines due to disappointing private payroll data and adjustments in tech sector sales strategies. As investors navigate these fluctuating conditions, identifying stocks trading below their intrinsic value can offer potential opportunities for those looking to capitalize on market inefficiencies.

As the U.S. stock market continues to show resilience, with major indexes like the Dow Jones and S&P 500 experiencing gains despite mixed economic signals such as a decline in private payrolls, investors are increasingly looking towards companies with solid growth potential and strong insider ownership. In this environment, stocks where insiders hold significant stakes can be particularly appealing, as they often indicate confidence in the company's future prospects and alignment of interests...

As the U.S. markets show resilience with major indexes rising despite mixed economic signals, investors are increasingly looking beyond traditional stocks to explore other opportunities. Penny stocks, often associated with smaller or newer companies, remain an intriguing area for those seeking potential value in less conventional investments. While the term may seem outdated, these stocks can still offer significant opportunities when backed by robust financials and a clear growth path.

If you are wondering whether Belite Bio's rapid rise is backed by real value or driven by hype, this article will walk you through what the numbers are really saying about the stock. After a sharp move higher, with the share price up 16.4% over the last week, 34.2% over the last month, and an eye catching 132.9% year to date, the market is clearly re rating the story and its risk profile. Much of the excitement has centered around Belite Bio's late stage ophthalmology pipeline, particularly...

Over the past year, many SPX Technologies, Inc. ( NYSE:SPXC ) insiders sold a significant stake in the company which...

As December 2025 unfolds, the U.S. stock market is experiencing a rebound with major indexes like the tech-heavy Nasdaq, blue-chip Dow Jones Industrial Average, and benchmark S&P 500 posting gains amid renewed investor confidence in tech and crypto-related stocks. In this dynamic environment, identifying promising small-cap stocks requires a keen understanding of market trends and insider actions that may signal potential opportunities for growth.

As of December 2025, the United States market has shown resilience with major indexes like the tech-heavy Nasdaq and blue-chip Dow Jones Industrial Average closing higher, fueled by a rebound in tech and crypto-related stocks. In this environment of renewed optimism, identifying high-growth tech stocks involves looking for companies that not only demonstrate robust financial performance but also have the potential to capitalize on emerging trends and technological advancements within a...

As of early December 2025, U.S. markets have shown resilience with major indexes closing higher amid a rebound in tech and crypto-related stocks. This environment presents opportunities for investors to explore stocks that may be trading below their fair value estimates, such as Lyft and others, by focusing on fundamental strengths and market positioning amidst the current economic landscape.

As the U.S. markets close higher with a rebound in tech and crypto-related stocks, investors are keenly observing opportunities across various sectors. Penny stocks, despite being an older term, continue to hold relevance for those seeking growth potential in smaller or newer companies. These stocks can offer significant returns when backed by strong financial health, making them an intriguing option for investors looking to uncover hidden value in quality companies.

We'd be surprised if Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shareholders haven't noticed that the Independent...

Motorcar Parts of America, Inc. ( NASDAQ:MPAA ) shareholders won't be pleased to see that the share price has had a...